Thyrocare Technologies Updates Webcast Link for Q4FY26 Earnings Call on May 7
Thyrocare Technologies issued a revised intimation on May 4, 2026, updating the webcast link for its Q4FY26 earnings conference call scheduled on May 7, 2026, at 5:30 PM IST. The board meeting on the same day will cover audited financial results for Q4 and FY ended March 31, 2026, and a final dividend recommendation. Senior management including Chairman Rahul Guha, CFO Vikram Gupta, and others will participate in the call.
*this image is generated using AI for illustrative purposes only.
Thyrocare Technologies Limited has issued a revised intimation to stock exchanges, updating the webcast link for its upcoming earnings conference call scheduled for May 7, 2026. The revision, filed on May 4, 2026, references the company's earlier intimation dated April 29, 2026, and confirms that all other details of the conference call remain unchanged.
Revised Conference Call Details
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has notified both the National Stock Exchange of India Limited and BSE Limited of the updated webcast link. The earnings conference call will be held on Thursday, May 7, 2026, at 5:30 PM IST, to discuss the company's audited financial results for the quarter and financial year ended March 31, 2026.
| Conference Call Details: | Information |
|---|---|
| Date: | May 7, 2026 |
| Day: | Thursday |
| Time: | 5:30 PM IST |
| Reporting Period: | Q4 and FY ended March 31, 2026 |
| Universal Access Numbers: | +91 22 6280 1408, +91 22 7115 8296 |
| Confirmation Number: | 6099720 |
| Revised Webcast Link: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=k7c1G75L |
| Event ID: | THY070526 |
Board Meeting Agenda
The board of directors meeting, also scheduled for May 7, 2026, will focus on two primary matters. Directors will consider and approve the audited standalone and consolidated financial results for both the quarter and financial year ended March 31, 2026. The board will also deliberate on recommending a final dividend for the financial year 2025-26, subject to board discretion.
| Meeting Details: | Information |
|---|---|
| Date: | May 7, 2026 |
| Day: | Thursday |
| Board Meeting Agenda: | Audited Financial Results Approval |
| Reporting Period: | Q4 and FY ended March 31, 2026 |
| Dividend Consideration: | Final Dividend Recommendation |
Senior Management Participation
The earnings call will feature comprehensive participation from Thyrocare's leadership team. The discussion will be led by Chairman, MD & CEO Mr. Rahul Guha, supported by Chief Commercial Officer Mr. Rajdeep Panwar and Chief Operating Officer Dr. Rameshinha. Financial insights will be provided by CFO Mr. Vikram Gupta, while Mr. Preet Joshi, Manager - Strategy & Investor Relations, will facilitate investor interactions.
| Management Team: | Designation |
|---|---|
| Mr. Rahul Guha: | Chairman, MD & CEO |
| Mr. Rajdeep Panwar: | CCO |
| Dr. Rameshinha: | COO |
| Mr. Vikram Gupta: | CFO |
| Mr. Preet Joshi: | Manager - Strategy & Investor Relations |
Trading Window Restrictions
In accordance with regulatory requirements, Thyrocare Technologies has implemented trading window restrictions to prevent insider trading. The trading window closed on April 1, 2026, affecting all designated persons and their immediate relatives from dealing in the company's equity shares. The window is set to reopen 48 hours after the results declaration.
| Trading Window Status: | Details |
|---|---|
| Closure Date: | April 1, 2026 |
| Applicable Regulations: | SEBI Insider Trading Regulations 2015 |
| Affected Parties: | Designated Persons and Immediate Relatives |
| Reopening Timeline: | 48 hours after results declaration |
Regulatory Compliance
Both the original board meeting intimation and the revised conference call notification have been filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Brijesh Kumar signed the revised notification on May 4, 2026, ensuring proper regulatory disclosure to stock exchanges where the company's shares are listed. The updated information is also available on the company's website at https://investor.thyrocare.com/financials/quarterly-financial-results/ .
Historical Stock Returns for Thyrocare Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.30% | -1.74% | +19.46% | -7.74% | +47.63% | +36.65% |
How might Thyrocare's FY2026 revenue growth and margin trajectory compare to peers like Dr Lal PathLabs and Metropolis Healthcare, given the competitive diagnostics landscape?
What factors could influence the board's decision on the quantum of the final dividend for FY2025-26, and how does it align with the company's historical dividend payout trends?
How has Thyrocare's strategic positioning evolved under PharmEasy's ownership, and what operational milestones might management highlight during the earnings call?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
